| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |